Journalist Alexander Levi from “ะช FM” describes how the company is implementing artificial intelligence in the work of medical companies and institutions.
Nvidia has announced partnerships with GE Healthcare and Johnson & Johnson. The agreements focus on the use of generative artificial intelligence in surgery and improving medical visualizations.
Previously, Nvidia introduced around 20 AI tools for healthcare. The fact that the vendor invested $50 million in Recursion Pharmaceuticals Inc. in 2023 alone underscores their interest in medicine and pharmacology. CNBC also mentions earlier collaborations between Nvidia and American companies Roche’s Genentech and Schrodinger in developing new drugs and treatment protocols.
Artificial intelligence can speed up the drug development process or find new uses for drugs that were not effective against the diseases they were designed for. Nvidia’s stock has grown by almost 100% since the beginning of 2024, and the events mentioned above are part of the reason for this growth. Nvidia not only provides hardware for running modern technologies but also offers ready-made software, tools, and scenarios that businesses can quickly implement.
Cloud platforms like NVIDIA Clara and BioNeMo help medical companies customize and deploy basic generative artificial intelligence models for drug development. According to surveys by EY Americas, around 41% of healthcare and biomedical science leaders at the end of 2023 stated that they are considering specific ways to use generative AI. Additionally, 7 out of 10 employees in medical and healthcare institutions are concerned about the implementation of artificial intelligence in the workplace.